Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI claims two brand/dose assertions (Zithromax 500 mg tablets and Z-Pak 5-day 250 mg schedule) that are not supported by the provided FDA label excerpt, and it only partially supports the Zmax formulation description. Only a single label section excerpt (3 Dosage Forms and Strengths) was provided, preventing full verification, but the specific mismatches shown indicate poor alignment with the available on-label text.
Category Scores
Accurate Statements
Zmax is an extended-release oral suspension form of azithromycin.
Partially supported by provided label excerpt: Zmax is described as an oral suspension containing azithromycin dihydrate equivalent to 2 g per bottle, and after constitution each mL contains 27 mg; however the excerpt does not explicitly confirm the term “extended-release.”
Unsupported Statements
Zithromax is a usual brand name for azithromycin 500 mg tablets.
The provided label excerpt (Section 3 DOSAGE FORMS AND STRENGTHS) only describes Zmax composition/concentration and does not mention Zithromax or 500 mg tablets/brand naming.
Z-Pak is a 5-day pack that provides a total of 2 × 250 mg on day 1 and 1 × 250 mg on days 2–5.
The provided label excerpt (Section 3 DOSAGE FORMS AND STRENGTHS) does not mention Z-Pak or any 5-day pack/dosing schedule.
Contradictions
Important Omissions
If the AI intended to differentiate products and schedules (e.g., Zmax vs Zithromax vs Z-Pak), the provided materials do not include the FDA label sections needed to verify dosing and product-specific administration instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Two claims include brand and dosing/schedule information that is not supported by the provided label excerpt; if such information were used to guide therapy without label confirmation, it could lead to product/schedule confusion.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported brand/dose assertions (Zithromax 500 mg tablets; Z-Pak 5-day 250 mg schedule) and incomplete support for the “extended-release” characterization of Zmax in the provided excerpt.
Suggested Improvement
Limit statements to what is present in the provided on-label excerpt (Zmax is an oral suspension; composition/concentration after constitution) and avoid asserting brand naming or 5-day dosing schedules unless verified against the appropriate FDA label sections.